FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088427711> ?p ?o ?g. }

• W3088427711 endingPage "e194" @default.
• W3088427711 startingPage "e186" @default.
• W3088427711 abstract "Purpose In the current study, we evaluated whether neoadjuvant chemoradiotherapy with reduced treatment volumes due to the exclusion of elective pelvic nodal irradiation is a feasible strategy for selected patients with locally advanced rectal cancer. Methods and Materials Patients with T2 low-lying/T3, N0-N1 rectal lesions without evidence of disease in the lateral lymph nodes were prospectively recruited. All patients underwent pretreatment testing, including computed tomography imaging of the chest, abdomen, and pelvis with intravenous contrast, pelvic magnetic resonance imaging with intravenous contrast, and 18-fluorodeoxyglucose positron emission/computed tomography. The clinical target volume included the primary tumor and the mesorectum with vascular supply containing the perirectal and presacral nodes, with the upper border at the S2/S3 interspace. The total radiation dose was 50.4 Gy, and fluoropyrimidine-based chemotherapy was associated concomitantly. The primary endpoint of the study was the reduction of gastrointestinal (GI) toxicity, and the secondary endpoints were pathologic complete response, local control, overall survival, and disease-free survival. Results Fifty-two patients (30 men, 22 women) with a median age of 67 years (range, 45-85 years) were enrolled in the study. Acute grade 3 GI toxicity was 7.6%, and there were no cases of grade 4 toxicity. Three patients (5.7%) developed a local recurrence. No relapse occurred in the lateral lymph nodes. The local control rate at 5 years was 96.1%. With a median follow-up time of 72.9 months (range, 2.5-127.6 months), the 3- and 5-year overall survival rates were 89.4% and 87%, respectively. The 3- and 5-year disease-free survival rates were 82.4% and 82.4%, respectively. Conclusions De-escalation of radiation therapy target volume reduces GI side effects without compromising efficacy in patients with rectal cancer. These results cannot be clearly extended to high-risk disease and need further evaluation in future randomized trials." @default.
• W3088427711 created "2020-10-01" @default.
• W3088427711 creator A5005999785 @default.
• W3088427711 creator A5012202473 @default.
• W3088427711 creator A5019046789 @default.
• W3088427711 creator A5020106424 @default.
• W3088427711 creator A5032638452 @default.
• W3088427711 creator A5034569772 @default.
• W3088427711 creator A5039880019 @default.
• W3088427711 creator A5045805982 @default.
• W3088427711 creator A5046611680 @default.
• W3088427711 creator A5057394271 @default.
• W3088427711 creator A5063528629 @default.
• W3088427711 creator A5065353986 @default.
• W3088427711 creator A5070267679 @default.
• W3088427711 creator A5071290979 @default.
• W3088427711 creator A5077246272 @default.
• W3088427711 date "2021-03-01" @default.
• W3088427711 modified "2023-09-29" @default.
• W3088427711 title "Long-Term Results of a Prospective Phase 2 Study on Volume De-Escalation in Neoadjuvant Chemoradiotherapy of Rectal Cancer" @default.
• W3088427711 cites W1969561516 @default.
• W3088427711 cites W1970659111 @default.
• W3088427711 cites W2000802860 @default.
• W3088427711 cites W2007296899 @default.
• W3088427711 cites W2018182127 @default.
• W3088427711 cites W2022680314 @default.
• W3088427711 cites W2037145385 @default.
• W3088427711 cites W2072201955 @default.
• W3088427711 cites W2073631512 @default.
• W3088427711 cites W2088235491 @default.
• W3088427711 cites W2095439981 @default.
• W3088427711 cites W2113353705 @default.
• W3088427711 cites W2120363614 @default.
• W3088427711 cites W2124297369 @default.
• W3088427711 cites W2124886112 @default.
• W3088427711 cites W2125373402 @default.
• W3088427711 cites W2125452425 @default.
• W3088427711 cites W2130192128 @default.
• W3088427711 cites W2132565869 @default.
• W3088427711 cites W2139247008 @default.
• W3088427711 cites W2184605405 @default.
• W3088427711 cites W2507943999 @default.
• W3088427711 cites W2754798215 @default.
• W3088427711 cites W2802688460 @default.
• W3088427711 cites W2889646458 @default.
• W3088427711 cites W2908927710 @default.
• W3088427711 cites W2912827532 @default.
• W3088427711 cites W2936877236 @default.
• W3088427711 cites W2945711754 @default.
• W3088427711 cites W3007265193 @default.
• W3088427711 cites W3029026801 @default.
• W3088427711 cites W3031039993 @default.
• W3088427711 cites W4250543953 @default.
• W3088427711 doi "https://doi.org/10.1016/j.prro.2020.09.009" @default.
• W3088427711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33002647" @default.
• W3088427711 hasPublicationYear "2021" @default.
• W3088427711 type Work @default.
• W3088427711 sameAs 3088427711 @default.
• W3088427711 citedByCount "1" @default.
• W3088427711 countsByYear W30884277112023 @default.
• W3088427711 crossrefType "journal-article" @default.
• W3088427711 hasAuthorship W3088427711A5005999785 @default.
• W3088427711 hasAuthorship W3088427711A5012202473 @default.
• W3088427711 hasAuthorship W3088427711A5019046789 @default.
• W3088427711 hasAuthorship W3088427711A5020106424 @default.
• W3088427711 hasAuthorship W3088427711A5032638452 @default.
• W3088427711 hasAuthorship W3088427711A5034569772 @default.
• W3088427711 hasAuthorship W3088427711A5039880019 @default.
• W3088427711 hasAuthorship W3088427711A5045805982 @default.
• W3088427711 hasAuthorship W3088427711A5046611680 @default.
• W3088427711 hasAuthorship W3088427711A5057394271 @default.
• W3088427711 hasAuthorship W3088427711A5063528629 @default.
• W3088427711 hasAuthorship W3088427711A5065353986 @default.
• W3088427711 hasAuthorship W3088427711A5070267679 @default.
• W3088427711 hasAuthorship W3088427711A5071290979 @default.
• W3088427711 hasAuthorship W3088427711A5077246272 @default.
• W3088427711 hasConcept C121608353 @default.
• W3088427711 hasConcept C126322002 @default.
• W3088427711 hasConcept C126838900 @default.
• W3088427711 hasConcept C141071460 @default.
• W3088427711 hasConcept C143409427 @default.
• W3088427711 hasConcept C168563851 @default.
• W3088427711 hasConcept C188816634 @default.
• W3088427711 hasConcept C203092338 @default.
• W3088427711 hasConcept C2776694085 @default.
• W3088427711 hasConcept C2778357063 @default.
• W3088427711 hasConcept C2778424827 @default.
• W3088427711 hasConcept C2779983558 @default.
• W3088427711 hasConcept C2989005 @default.
• W3088427711 hasConcept C31760486 @default.
• W3088427711 hasConcept C509974204 @default.
• W3088427711 hasConcept C526805850 @default.
• W3088427711 hasConcept C71924100 @default.
• W3088427711 hasConceptScore W3088427711C121608353 @default.
• W3088427711 hasConceptScore W3088427711C126322002 @default.
• W3088427711 hasConceptScore W3088427711C126838900 @default.
• W3088427711 hasConceptScore W3088427711C141071460 @default.
• W3088427711 hasConceptScore W3088427711C143409427 @default.

• next